No Prescription

Alpha Index I

No Prescription » Products » Alpha Index I

List of Drugs:

A  B  C  D  E  F  G  H  I  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Z  #

Products I:

IBUGESIC Advil

I-Clenz

IDROFOS Boniva

IF1 Patanol

IF2 Eye Drops Patanol

Ilosone (Erythromycin)

Imdur Generic Isosorbide Mononitrate

Imdur (Isosorbide Mononitrate)

IMIDARA Aldara

Imigran Imitrex

Imiquad Aldara

Imitrex (Sumatriptan)

Immunity & Liver Support

Imodium Generic Loperamide

Imodium (Loperamide)

Imuran Azasan

Imuran (Azathioprine)

IMUSPORIN Neoral

INDERAL Generic Propranolol

Inderal (Propranolol)

Inderide (Propranolol + Hydrochlorothiazide)

Indivan Crixivian

Indocin (Indomethacin)

Insect Repellant Natural

INTAGRA Coverata

Intalith CR Eskalith

Intazide Colazal

IOBET Betoptic

I Pill Plan B

Ipravent Inhaler Atrovent

I Profen Advil

IPSITA ATACAND

IROVEL Avapro

IROVEL H AVALIDE

ISMO Imdur

Ismo Retard Imdur

Isonorm SR Imdur

Isoptin Calan

Isoptin SR Calan

Isordil Generic isosorbide Dinitrate

Isotroin Accutane

Itoprid Generic Itopride hydrochloride

Itraspor Mikro Sporanox

Itraspor Sporanox

Previous  Next

No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.